Bringing the fundamentals into focus…
Back to Ultragenyx Pharmaceutical Inc.
How Ultragenyx Pharmaceutical Inc. stacks up
RARE · against 437 other Healthcare companies of similar size
Profitability
16/ 100
Near the bottom of its peers.
Ranked #379 of 438 · scores higher than 12% of peers
Bars: peers in each 10-point band of the profitability score39 peers with a profitability score of 10–19, including RARE · Click a bar to see the companies
Why profitability scores 16?
Weighted metrics compared with all Healthcare companies.Mainly because of its return on assets, operating margin and return on invested capital, which are weaker than most Healthcare peers.
- a lower return on assets: weaker than 92% of peers. Return on assets: -46.4% vs peer median 1.7%
- a thinner operating margin: weaker than 86% of peers. Operating margin: -73.6% vs peer median 7.1%
- a lower return on invested capital: weaker than 83% of peers. Return on invested capital: -32.1% vs peer median 4.7%
Metric by metric
Position: dot = RARE, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RARE | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Return on invested capitalHigher is better · 413 reported | -32.1% | 5.4% | 15% | 33% | |
| Operating marginHigher is better · 410 reported | -73.6% | 7.0% | 11% | 33% | |
| Return on assetsHigher is better · 422 reported | -46.4% | 1.9% | 5% | 33% | |
| Return on equityHigher is better · 406 reported | Not reported | 4.1% | — | — | Context only |
| Gross marginHigher is better · 453 reported | -20.8% | 47.4% | 2% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by profitability score
Top 5 and the companies ranked around RARE| Rank | Company | Market cap | Profitability | Overall |
|---|---|---|---|---|
| 1 | 174.8B INR (≈$2.1B) | 100 | 73 | |
| 1 | 97.3B INR (≈$1.2B) | 100 | 80 | |
| 3 | 12.3B CNY (≈$1.7B) | 99 | 85 | |
| 3 | 11.2B DKK (≈$1.7B) | 99 | 59 | |
| 3 | 51.3B ZAR (≈$2.8B) | 99 | 73 | |
| 377 | 1.9B USD | 17 | 32 | |
| 379 | 1.5B USD | 16 | 26 | |
| 379 | 1.1B USD | 16 | 50 | |
| 379 | 1.3B USD | 16 | 30 | |
| 379 | 1.6B USD | 16 | 24 | |
| 379 | 1.5B USD | 16 | 39 | |
| 379 | 2.5B USD | 16 | 31 | |
| 385 | 1.7B USD | 15 | 30 | |
| 385 | 1.3B USD | 15 | 29 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score